Creative Medical Technology Holdings, Inc. fell 2.03% in after-hours trading, as the company, a commercial-stage biotechnology firm focused on innovative biotherapeutics, including immunotherapies and endocrinology, reported on the availability of its CaverStem and FemCelz kits for treating sexual dysfunction through its subsidiaries in eight U.S. locations.
Comments
No comments yet